Clinical Trial

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Study acronym: COMPASS 2-AD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Trial sites expanded: 55 -> 88 locations 2026-05-30
notable Trial sites expanded: 35 -> 55 locations 2026-04-24
Trial Details
NCT Number NCT07105488
Lead Sponsor Bluefin Biomedicine, Inc.
Conditions Atopic Dermatitis (AD)
Enrollment 225 participants
Start Date 2025-07-15
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30